CD274 and breast cancer: A reporter polymeric nanoparticle, carrying paclitaxel, and which incorporated PD-L1-blocking antibodies through conjugation with PEG, showed enhanced antitumor activity in preclinical models of lung and breast cancer, leading to significantly decreased tumor volumes (p < 0.001) compared to control nanoparticles [100].